DPI-287

DPI-287 is an experimental antiviral drug that was under development by Deciphera Pharmaceuticals. It was designed as a potent inhibitor of the NS5B RNA-dependent RNA polymerase (RdRp) of hepatitis C virus (HCV). The NS5B polymerase is essential for the replication of the HCV genome, making it a key target for antiviral therapies.

The drug aimed to block the activity of the NS5B polymerase, thus preventing the virus from replicating and spreading within the host. DPI-287 underwent preclinical and early clinical trials to assess its safety and efficacy. These studies evaluated the drug's ability to reduce HCV viral load in infected individuals.

While showing some promising results in early stages, the development of DPI-287 was eventually discontinued. This discontinuation was likely due to a number of potential factors, including efficacy concerns, safety issues identified during trials, the emergence of more effective treatments, or strategic business decisions by the developing company. The hepatitis C treatment landscape has evolved significantly, with the introduction of direct-acting antiviral (DAA) therapies that offer higher cure rates and shorter treatment durations. These advancements likely contributed to the decision to cease development of DPI-287. Further research and clinical trial data regarding its complete profile and reasons for discontinuation would be needed for a more comprehensive analysis.